NASDAQ:FTRE - Nasdaq - US34965K1079 - Common Stock - Currency: USD
Taking everything into account, FTRE scores 3 out of 10 in our fundamental rating. FTRE was compared to 55 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of FTRE have multiple concerns. FTRE is valued quite cheap, but it does not seem to be growing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -25.32% | ||
ROE | -92.04% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 20.21% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.22 | ||
Debt/FCF | 8.36 | ||
Altman-Z | 0.44 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 0.97 | ||
Quick Ratio | 0.97 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 13.63 | ||
Fwd PE | 6.84 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 3.4 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
5.45
-0.01 (-0.18%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 13.63 | ||
Fwd PE | 6.84 | ||
P/S | 0.18 | ||
P/FCF | 3.4 | ||
P/OCF | 3 | ||
P/B | 0.57 | ||
P/tB | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -25.32% | ||
ROE | -92.04% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 20.21% | ||
FCFM | 5.4% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.22 | ||
Debt/FCF | 8.36 | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 23.04% | ||
Cap/Sales | 0.71% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 0.97 | ||
Quick Ratio | 0.97 | ||
Altman-Z | 0.44 |